Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Iambic Therapeutics

Biotech & Life Sciences · San Diego, United States · Founded 2019

Iambic Therapeutics is a clinical-stage biotechnology company that leverages its proprietary AI-driven discovery platform to develop novel therapeutics, with a primary focus on oncology and neurological diseases. The company's platform utilizes advanced AI models and automated experimental approaches to accelerate the identification and development of drug candidates. This technology enables a significant reduction in the time and data required for predicting molecular properties, thereby streamlining the drug discovery process. The business model encompasses both the independent development of a proprietary pipeline of drug candidates and strategic partnerships with other pharmaceutical companies. These collaborations leverage Iambic's AI capabilities for joint drug discovery efforts. The company generates revenue through the advancement of its internal pipeline and through milestones and royalties from its partnerships. Iambic Therapeutics serves the pharmaceutical and biotechnology markets by providing a new avenue for the discovery of treatments for complex diseases. Keywords: AI-driven drug discovery, oncology therapeutics, neurological diseases, clinical-stage biotechnology, generative AI, drug development, molecular properties prediction, pharmaceutical partnerships, cancer treatment, automated experiments

Valuation
$100–500M
Latest valuation · 2025
Unlock exact value
Revenue
$1–10M
Latest reported FY
Unlock exact value
Headcount
100–500
Current team size
Unlock exact value
Total funding Pre-IPO
$100–500M
Unlock exact value

Investors

23 investors on Iambic Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 14 investors entered at this stage
Coatue Management
Catalio Capital Management
Sequoia
OrbiMed
Nexus Ventures
Freeflow Ventures
Abingworth
Ascenta Capital
Nvidia
Illumina Ventures
Gradiant
Exor Ventures
Mubadala Capital
Qatar Investment Authority
Series B+ 9 investors entered at this stage
Alexandria Venture Investments
Alumni Ventures
Terra Magnum Capital Partners
Regeneron Ventures
Everbright Biofund
Pegasus Tech Ventures
Tao Capital Partners
Wilson Sonsini
ARK Invest

Global footprint

Where Iambic Therapeutics has talent and traffic

Workforce by country
7 countries with
team presence
🇺🇸 United States90.6%
🇬🇧 United Kingdom4.3%
🇧🇷 Brazil1.7%
🇨🇦 Canada0.8%
🇩🇰 Denmark0.8%
Top 5 of 7 shown

Talent graph

The shape of Iambic Therapeutics's talent

Dealroom maps Iambic Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

13 team members profilednamed & role-tagged by Dealroom
159 employeestotal headcount
6 executives & foundersidentified by name
DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Iambic Therapeutics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about Iambic Therapeutics

An AI-synthesized read of the highest-engagement posts about Iambic Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Iambic Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.